Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PRF1 | P14222 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745510 | 0.86 | KDM4E (0.35) | KDM4ERXFP1NPSR1GLATNK2 | |
| SCHEMBL31745443 | 0.85 | TNK2 (0.34) | KDM4EDRD1TNK2AOC3MAPT | |
| SCHEMBL31745562 | 0.84 | KDM4E (0.37) | KDM4ERXFP1NPSR1GLATNK2 | |
| SCHEMBL31745483 | 0.80 | MAPT (0.36) | KDM4ERXFP1NPSR1GLATNK2 | |
| SCHEMBL31745568 | 0.75 | KDM4E (0.34) | KDM4ERXFP1NPSR1GLATNK2 | |
| SCHEMBL31745428 | 0.73 | KDM4E (0.36) | KDM4ERXFP1NPSR1GLATNK2 | |
| SCHEMBL31745440 | 0.72 | PRF1 (0.35) | KDM4ERXFP1NPSR1GLATNK2 | |
| SCHEMBL31745429 | 0.71 | KDM4E (0.36) | KDM4ERXFP1NPSR1GLAMAPT | |
| SCHEMBL31360456 | 0.71 | PRF1 (0.35) | KDM4ERXFP1MAPTPRF1 | |
| SCHEMBL31745488 | 0.70 | TNK2 (0.39) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | KDM4E 3025/4885RXFP1 1295/4885NPSR1 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.